JPS5959620A - Preparation of blood serum - Google Patents
Preparation of blood serumInfo
- Publication number
- JPS5959620A JPS5959620A JP57169044A JP16904482A JPS5959620A JP S5959620 A JPS5959620 A JP S5959620A JP 57169044 A JP57169044 A JP 57169044A JP 16904482 A JP16904482 A JP 16904482A JP S5959620 A JPS5959620 A JP S5959620A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- blood
- animal
- portal vein
- branch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title description 2
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 210000003240 portal vein Anatomy 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 6
- 210000005161 hepatic lobe Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 14
- 210000003494 hepatocyte Anatomy 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 239000004952 Polyamide Substances 0.000 abstract description 2
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 238000001962 electrophoresis Methods 0.000 abstract description 2
- 229920002647 polyamide Polymers 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 210000003462 vein Anatomy 0.000 abstract description 2
- 241001582888 Lobus Species 0.000 abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 230000002440 hepatic effect Effects 0.000 abstract 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101100287595 Caenorhabditis elegans kin-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】 本発明は血清の製造方法に関する。[Detailed description of the invention] The present invention relates to a method for producing serum.
従来、肝臓葡部分切除したラットの面済(再生肝血清)
には、肝細胞の増殖全促進させる佳作用を有する血清ケ
得るべく、種々P吋した結果、本発明に到達しfr:、
。Conventionally, treatment of rats with partial liver resection (regenerated liver serum)
In order to obtain a serum that has the positive effect of promoting the proliferation of hepatocytes, the present invention was achieved as a result of various efforts.
.
すなわち、本発明の′)、】旨は、温血せきつい動物の
門脈木幹又はその肝葉に入る分岐部分の少なくとも一部
を結紮した後、1啓動物の血、′夜を採取し、この血液
よりJr■清盆調裂すること全特徴とする血清の製造方
法にある。That is, the object of the present invention is to ligate at least a part of the portal vein trunk of a warm-blooded animal or its branching part that enters the liver lobe, and then collect the blood of the animal, The method for producing the serum is characterized by the fact that it is extracted from this blood.
以下1本発明ケ詳、filtlに説明−rる。The present invention will be explained in detail below.
本発明における温面せきつい動物としては、ラット、マ
ウス、ニワトリ、ヤギ、ウシ、ウサギ、ブタ、ウマ等が
挙げられる。Examples of warm-sensitive animals in the present invention include rats, mice, chickens, goats, cows, rabbits, pigs, horses, and the like.
本発明方法においては、これらの動物の門脈木幹又はそ
の肝葉に入る分岐lτli分の少なくとも一部が結紮さ
れる。In the method of the present invention, at least a portion of the portal vein trunk of these animals or the branch lτli that enters the liver lobe is ligated.
門脈は、消化器とひ臓からの血i! k集めて肝臓に運
ぶ静脈系であり、肝11FIの香華に、分岐して進入し
ている。The portal vein carries blood from the digestive system and spleen! It is a venous system that collects k and transports it to the liver, and branches into the fragrant duct of the liver 11FI.
本発明方法においては、この、+lA入部分、すなわち
、門脈の肝臓各音に入る分岐部、又は門脈木幹の一部又
は全部を絹糸等で結紮する。結紮孕部分的に行なう場合
としては、たとえば分、峡部の//、2〜.2/3程度
を結紮する方法が挙げられる。In the method of the present invention, this +1A entry portion, that is, the branching portion where the portal vein enters each liver organ, or a part or all of the portal vein tree trunk is ligated with silk thread or the like. If the ligation is to be carried out partially, for example, the isthmus is ligated, 2 to 2 minutes. An example of this method is to ligate about 2/3 of the tissue.
たとえば、 、2/、3を結紮する」ハ合と【7てtx
t、門脈木幹から左葉、中葉、右葉に入る三つの部分の
うらの二つケ結紮する方法が挙げられろ。For example, to ligate , 2/, 3 and 7
T. List the method of ligating the backs of the three parts that enter the left lobe, middle lobe, and right lobe from the portal vein trunk.
上記結紮後、所定時間たと、t &、lr数時間以上経
過した後に、門脈の少なくとも一部を結紮した上記ウシ
等の動物の血液が常法により採取される。After a predetermined period of several hours or more has elapsed after the ligation, the blood of the animal such as the cow whose portal vein has been ligated at least in part is collected by a conventional method.
次いで、採11vシた血液より血清が調$”4される。Next, serum was prepared from the collected blood.
たとえば、上記血液ケ室渇で凝固させた後、遠心分離等
により、その上清7.C1112イ!$−fることによ
り目的とする血清ケ得る。浦心分雅によるときりま1通
常r、θOθ〜/、2.θθ09稈度で数分以上行なわ
れる。For example, after the blood is coagulated by drying, the supernatant 7. C1112i! The desired serum amount is obtained by $-f. Tokirima 1 normal r, θOθ~/, 2. by Urashin Bunga. It is carried out for several minutes or more at a culm degree of θθ09.
本発明において(よ、得られた血清ケさらに加熱および
/又は透析することによりTff 製することができる
。In the present invention, Tff can be produced by further heating and/or dialysis of the obtained serum.
加熱は通當to〜1OOC程度で1分以上行なわれ、熱
変件した高分子タンパクは沈澱除去される。Heating is generally carried out for 1 minute or more at approximately 1 OOC, and thermally denatured high molecular weight proteins are precipitated and removed.
または、透析は、カルシウム′に実質的に含有しない塩
類溶液、好ましくはさらにマグネシウムをも笑質的に含
有しない塩類溶液ケ月1いて行なわれる。Alternatively, dialysis is carried out in a saline solution that is substantially free of calcium, preferably also substantially free of magnesium.
この塩類溶液としてはカリウム、ナトリウム、特にカリ
ウム全含有するものが好適である。As this salt solution, a solution containing potassium and sodium, particularly one containing all potassium, is suitable.
上記塩類としては、たとえば、タイロード溶液(Tyr
oae’8Pflu tton ) (以下、「CMF
溶液」という)が使用される。Examples of the above-mentioned salts include Tyrode's solution (Tyr
oae'8Pflutton) (hereinafter referred to as "CMF
solution) is used.
この溶液の組成Vi1次のとおりである。The composition of this solution Vi1 is as follows.
NapH,00Na2HPO4/ 、/ jKO/
0.20 KH2]”0409.20(g/l
)
上記透析処理により、血清中の低分子計成分が除去され
る。NapH, 00Na2HPO4/ , / jKO/
0.20 KH2]”0409.20(g/l
) The above dialysis treatment removes low molecular weight components in the serum.
本発明に係る血清は1次のような性質r有する。The serum according to the present invention has the following properties.
a)OOnA(コンカナバリンA)−セファロースクロ
マトグラフィーにより溶出される。a) OOnA (Concanavalin A) - eluted by Sepharose chromatography.
すなわち、多糖類又は糖タンパク質の性状を示さない。That is, it does not exhibit properties of polysaccharides or glycoproteins.
b) SDSポリアミドゲルによる電気泳動図ハ1分
子猾約/ A 、 000〜III 、 000に3本
のバンドを有する。b) Electropherogram obtained by SDS polyamide gel has three bands at 1 molecule interval/A, 000 to III, 000.
C) 動物による種4?異性を示さない。C) Animal species 4? Do not show the opposite sex.
d) 肝細胞の増殖促進作用を有し、かつ、他の組繊細
胞の培養においてもウシ由来の胎児血清、準胎児血清又
は子牛血清と同様の培養効果ケ示す。d) It has a proliferation-promoting effect on hepatocytes, and also exhibits the same culture effect as bovine fetal serum, quasi-fetal serum, or calf serum in culturing other tissue cells.
以上のように、本発明方法によれば従来に比し、よシ簡
易な方法で培養効果の優れた血清ケ得ることができ、さ
らに肝機能促進剤等としての用途も期待される。As described above, according to the method of the present invention, it is possible to obtain serum with excellent culture effects in a simpler manner than in the past, and it is also expected to be used as a liver function promoter.
以下、本発明′fc英施例により、さらに詳細に説明す
るが1本発明はその要旨ケ超えないかぎゃ、これら実施
例に限定されるものではない。Hereinafter, the present invention will be explained in more detail with reference to examples, but the present invention is not limited to these examples as long as the gist thereof is not exceeded.
実施例/
生後約3ケ月のSprauge −Dawley系雄ラ
ット系間ラット/3ヶ結紮し、その面消ケさらに加熱、
透析して得られた血清ケ新生児ラット肝細胞培養に添加
し、その増殖孕みた。Example: Sprauge-Dawley male rats approximately 3 months old;
The serum obtained by dialysis was added to neonatal rat hepatocyte culture to induce proliferation.
(【)門脈の結紮
動物を軽くエーテル辛酸し、開腹後図−/に示すように
門脈本幹ti+の中葉、左葉にはいる部分(21′に3
号絹糸にて結紮した。結紮後、UMk70%エタノール
で消毒し、もとにもとし腹壁上二層縫合した。([) After the portal vein was ligated, the animal was slightly acidified with ether, and after laparotomy, the part that enters the middle lobe and left lobe of the main portal vein ti+ (3 at 21') is shown in Figure -/.
It was ligated with silk thread. After ligation, the tissue was disinfected with UMk 70% ethanol, and the original tissue was sutured in two layers on the abdominal wall.
+21 採血、血清の調製
術後、2ケ時間目に、動物勿+i’f: <エーテル麻
酔し、頚動脈ヶ切断し、全血液を採取した。+21 Blood collection and serum preparation Two hours after the operation, the animals were anesthetized with ether, the carotid artery was cut, and the whole blood was collected.
採取した血液は、室温で凝固させ、グCで/晩装置した
のち、j00X9で1分間遠心分離し、その上清全血清
とした。上述のようにして得た血清は使用前まで一!θ
Cで凍結保存した。The collected blood was allowed to coagulate at room temperature, incubated overnight with GAC, and then centrifuged for 1 minute with J00X9 to obtain the supernatant of total serum. The serum obtained as described above should be used only once before use! θ
It was stored frozen at C.
+31.770熱及び透析処理
上述の方法で得た血清@、1oor2の湯浴中で2分間
加熱し、熱変性したタンパク質を/、2000 x 9
で20分間遠心分離し、沈殿として取り除き、その上清
音、CMF俗液で・、24を時間透析し、精製した血清
ケ得た。+31.770 Heat and dialysis treatment Serum obtained as described above was heated for 2 minutes in a 1oor2 water bath and the heat-denatured protein was heated at 2000 x 9
The supernatant was centrifuged for 20 minutes and removed as a precipitate, and the supernatant was dialyzed against CMF ordinary solution for 24 hours to obtain purified serum.
(4)試 験
基本培地は、EaglθMFjM忙(組成を表−lに示
す)使用し、実験区には加熱、透析1−た閂脈奮結紮し
たラット面渭詫・70%添加し。(4) Test The basic medium used was EaglθMFjM (composition shown in Table 1), and 70% of heated, dialyzed, and ligated rat phlegm was added to the experimental area.
対照区には疑似手術rしたラット血清)f10%添加し
た。結果金回−2及び1閃−3に示す。In the control group, 10% sham-operated rat serum) was added. The results are shown in Kin-2 and 1-3.
なお、′fr生児ラッう肝細/Ifii培養方tノ、及
び卸1胞数の測定方法は次のとおりである。In addition, the method of culturing liver cells/Ifii of newborn rats and the method of measuring the number of whole cells are as follows.
a) 新生児ラット肝#411胞培硲方法生後を日目の
新生児ラットg−10頭
を断首、放血し、70%エタノールで消毒後、無菌箱の
中に入ノ11、以後遠心分離以外はすべて無菌箱中で操
作し/こ。J復部葡ハザミで切開し、全肝JIS忙とり
だし、cMF?dfG[でよく洗浄し5カミソリの刃で
約/朋角の大きさ罠細切し念。細切した肝#!全0.0
!チコラーゲナーゼ
(Hanks溶液に溶かしたもの。該溶液の組成は、表
−に示す)で377::、1時間・fンキユベートし、
その後二重のナイロンガーゼでろ過し、 cMF溶液
で洗浄後、再度二重のナイロンガーゼでろ過し几。a) Neonatal rat liver #411 cell culture method: Decapitate and exsanguinate 10 newborn rat liver #411 cells, disinfect them with 70% ethanol, and place them in a sterile box. After that, except for centrifugation, All operations are performed in a sterile box. I made an incision with J Fukube's scissors, and the whole liver was taken out by JIS, cMF? Wash thoroughly with dfG and cut into pieces approximately the size of a square inch with a razor blade. Shredded liver #! Total 0.0
! Incubate with ticolagenase (dissolved in Hanks solution; the composition of the solution is shown in Table 1) for 1 hour.
After that, filter through double nylon gauze, wash with cMF solution, and filter again through double nylon gauze.
ろ過した粗細胞浮遊液葡poy、g、2分間低速遠心分
離し、肝夾質測胞全集め、その上清全取り除き、ふたた
びCMF溶lrl’c刀nえ、中た〈ピペ゛ンティング
し、同様に遠心分子flI L、以下同じ遠心操作を2
回くす返(〜h +r(It胞?よく洗浄した。The filtered crude cell suspension was centrifuged at low speed for 2 minutes at G to collect all the liver particles, remove all the supernatant, dissolve in CMF again, and pipette into the medium. , Similarly, centrifuge the molecule flI L, and the same centrifugation operation is carried out 2 times.
Repeat several times (~h + r(It cells? Wash well.
洗浄した翁l胞?目的とする培地にいれ、プラスチック
シャーレ(JJtX/j龍)に各7゜j ccずつ細胞
をまき、J7c。Washed old man's cyst? Place the cells in the desired culture medium and sow 7°j cc of cells in each plastic petri dish (JJtX/jryu), J7c.
りj%air−1%002の気相で培養した。The cells were cultured in a gas phase of 1% air-1%002.
b) 細胞数の測定方法
培養後* 1111定日にシャーレをとり出し、培地?
取り除き06λ!チドリプシン(Cしよりにがし比。そ
の細胞浮遊液をjθO×9,10分間遠心分1’l’F
[、、細胞ケ年めそれ葡既知清のOM lr H5H液
に溶かし、トリパンブルーで染色後、肝T質の生細胞の
みケ、ヘマトメータにより7則足した(トリバンブルー
の染色により核の染まらないものケ生細胞とした。)。b) How to measure the number of cells After culturing * 1111 Take out the Petri dish on a regular day and check the culture medium.
Remove 06λ! Tidrypsin (C).The cell suspension was centrifuged for 10 minutes at jθO x 9 at 1'l'F.
[,,Cells were dissolved in OMlr H5H solution of a well-known serum, and after staining with trypan blue, only living cells of liver T substance were added using a hematometer (nuclei were not stained by trivan blue staining). Monoke living cells).
なお、各3個のシャーレン測定し、ぞの117−均値全
細胞数とした。In addition, each 3 petri dishes were measured and used as the 117-average total cell number.
注/) 再生肝擬似手術方法
動物全群くエーテル麻酔し、固足台
に仰臥位に固定饅1手術野?剃毛、70%エタノールで
消毒し、白線上?剣状突起まで、3〜グー切開し、その
後、前胸部を指で圧迫し、肝Mケj分111Jはど腹腔
外に露出した後、70%エタノールで消毒し、腹腔内に
もどした。腹壁43号絹糸により二重縫合し、縫合部ア
クリフラビンで消毒した(なお手術は常に午前
io時半から7.2時の間におこなつ7j、、l。Note/) Regeneration liver sham surgery method: All animals were anesthetized with ether and fixed in supine position on a firm foot platform. Shaving, disinfecting with 70% ethanol, above the white line? A 3 to 3 mm incision was made up to the xiphoid process, and then the anterior thorax was compressed with fingers to expose the 111 J portion of the liver outside the peritoneal cavity, which was then disinfected with 70% ethanol and placed back into the peritoneal cavity. Double sutures were made to the abdominal wall using No. 43 silk thread, and the suture area was disinfected with acriflavin (surgery was always performed between 1:30 a.m. and 7:2 a.m.).
表−′F″a″1°MEMの組成 (”17/l)表
−,2、Hanks溶液の組成
(9/l )
pH7,弘
図−λ、−3に示すように加熱、透析した門脈を結紮し
たラットの血清は、疑似手術血清にくらべ有意な増殖が
みられた。Table - Composition of 1°MEM (17/l) Table 2, Composition of Hanks solution (9/l) pH 7, Hirotu - λ, -3 Sera from rats whose veins were ligated showed significant proliferation compared to serum from sham surgery.
図−/は、ラット門脈の結紮部位の一例荀示す図であシ
、IJ−,2は新生児ラット肝細胞の、Yll胞数の変
化?示し、図−3は肝細胞の増殖曲線である。
図−/において/は門脈木幹コは結紮部分全示す。
出 願 人 三菱化成工業株式会社
代 理 人 弁理士 長谷用 −ほか1名
図−1
配−2Figure-/ is a diagram showing an example of a ligated site of a rat portal vein.IJ-,2 is a change in the number of Yll cells in neonatal rat hepatocytes. Figure 3 shows the growth curve of hepatocytes. In Figure 1, the portal vein trunk shows the entire ligated portion. Applicant: Mitsubishi Chemical Industries, Ltd. Agent: Patent attorney: Yo Hase - and one other figure - 1 - 2
Claims (1)
葉に入る分岐部分の少なくとも一部ケ結紮した後、該動
物の血液を採取し、この血液より血清?調製することを
特徴とする血清の製造方法。 (2(温面せきつい動物の門脈本幹またはその肝葉に入
る分岐部分の少なくとも一部ケ結紮した後、該動物の血
液全採取し、この血液より血清?:調製し、次いで得ら
れた血清を加熱および/又は透析すること全特徴とする
血清の製造方法。[Claims] After ligating at least a portion of the portal vein trunk of a bloodthirsty animal or its branching portion that enters the liver lobe, the animal's blood is collected, and from this blood serum is extracted. A method for producing serum, which comprises: (2) After ligating at least a portion of the portal vein main trunk or its branching portion that enters the liver lobe of a warm-tempered animal, the whole blood of the animal was collected, and serum was prepared from this blood. A method for producing serum, the entire process comprising heating and/or dialysis the serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57169044A JPS5959620A (en) | 1982-09-28 | 1982-09-28 | Preparation of blood serum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57169044A JPS5959620A (en) | 1982-09-28 | 1982-09-28 | Preparation of blood serum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5959620A true JPS5959620A (en) | 1984-04-05 |
Family
ID=15879274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57169044A Pending JPS5959620A (en) | 1982-09-28 | 1982-09-28 | Preparation of blood serum |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5959620A (en) |
-
1982
- 1982-09-28 JP JP57169044A patent/JPS5959620A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4066083A (en) | Sterile surgical collagen product | |
| KNAPP et al. | Injectable collagen for soft tissue augmentation | |
| JP4025897B2 (en) | Preparation of collagen | |
| NO317699B1 (en) | Process for preparing a protein concentrate coagulable with thrombin and containing mostly fibrinogen, endogenous factor XIII and fibronectin. | |
| RU2008915C1 (en) | Method of producing agent for stimulating connections between parts of living mineralized tissue | |
| JPS6237020B2 (en) | ||
| US4621631A (en) | Process for the production of a bonded collagen fiber sheet | |
| JPH07501465A (en) | Fetal membrane tube for nerve and vascular grafts | |
| CN103705979B (en) | For functional organization's engineering material of CO2 laser weld and preparation thereof and purposes | |
| CN107744413A (en) | The preparation method of new Valved allograft | |
| Fantl | A comparative study of blood coagulation in vertebrates | |
| CN111084900A (en) | Preparation method and application of acellular fish skin matrix | |
| JPWO2018221402A1 (en) | Method for producing decellularized material for transplantation and graft composition comprising biocompatible material containing the material | |
| US5354269A (en) | Method for treating cancer resections | |
| KR101697324B1 (en) | Biocompatible Collagen and Methods for Preparing the Same | |
| RU2353397C2 (en) | Bioabsorbable collagen matrix, method of production and application | |
| JPS5959620A (en) | Preparation of blood serum | |
| SCHWARZ et al. | The characterization and partial purification of hepatocyte proliferation factor | |
| CN108379650A (en) | A kind of novel rush wound healing biogum and its application | |
| JPH0148886B2 (en) | ||
| JPS60501540A (en) | Extracellular matrix body implants and means and methods for their manufacture and use | |
| JPS60243019A (en) | Hepatic cell proliferation factor | |
| JPH04288165A (en) | Organ implant and manufacture thereof | |
| McLellan | The maggot treatment of osteomyelitis | |
| EP0686401A2 (en) | Living-tissue adhesive and blood coagulant |